Switzerland

BMI Core View: The uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which... 2012-05-08

BMI View: The patent expiry of Diovan (valsartan) in the US in 2012, continuing falling revenue due to generic competition to Diovan in Europe and the lower sales expectations for Rasilez/Tekturna... 2012-04-25

BMI View: The expected growth of the Switzerland's ageing population over the next 50 years is to have an unprecedented impact on the demand for healthcare. The elderly require more... 2011-11-30

BMI Core View: Governments will increasingly impose price controls on pharmaceuticals. Drugmakers have generally charged what the market will bear in developed and emerging markets.... 2011-11-29

BMI View: Acino's focus on advanced drug delivery systems, in addition to its product portfolio of innovative and generic medicines, will provide the company with opportunities to increase... 2011-09-14

BMI View: Uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which is increasingly... 2011-08-26

BMI View: Despite the massive appreciation of the Swiss franc against the euro and the dollar through 2010 - and with the trend continuing into 2011 - we believe the high value-added... 2011-08-22

BMI Core View: Personalised medicines will play a greater role in the treatment of patients. They offer fewer side-effects and treat illnesses more efficiently than wide-spectrum therapeutics.... 2011-08-18

BMI View: Novartis will outperform rival pharmaceutical companies over the medium term and therefore continue to be an attractive prospect for investment. The Basel-based firm increasingly... 2011-07-21

BMI View: While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability will work towards increasing... 2011-05-25